contezolid acefosamil/contezolid for Communicable Diseases

Phase-Based Progress Estimates
Harbor-UCLA Medical Center, Torrance, CA
Communicable Diseases+4 More
contezolid acefosamil (IV)/contezolid (PO) - Drug
All Sexes
What conditions do you have?

Study Summary

This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.

Eligible Conditions

  • Communicable Diseases
  • Infection; Diabetic Foot

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Communicable Diseases

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 28-35 days after End-of-Therapy (EOT)

Day 35
Adverse events - symptoms reported by subjects
Clinical laboratory assessment - complete blood count
Vital signs - heart rate
Day 35
Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Communicable Diseases

Trial Design

2 Treatment Groups

1 of 2
contezolid acefosamil/contezolid
1 of 2
Active Control
Experimental Treatment

865 Total Participants · 2 Treatment Groups

Primary Treatment: contezolid acefosamil/contezolid · No Placebo Group · Phase 3

contezolid acefosamil/contezolid
Experimental Group · 1 Intervention: contezolid acefosamil (IV)/contezolid (PO) · Intervention Types: Drug
ActiveComparator Group · 1 Intervention: Linezolid (IV and PO) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 28-35 days after end-of-therapy (eot)
Closest Location: Harbor-UCLA Medical Center · Torrance, CA
2006First Recorded Clinical Trial
5 TrialsResearching Communicable Diseases
75 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have diabetes mellitus (type 1 or 2).
You have a foot infection that started at or below the malleolus and does not extend above the knee.
You have moderate or severe infection of the foot.
You have had a foot infection for 14 days or less.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.